Zhitong Financial APP News, Dacheng Biotechnology (00809) released unaudited results for the year ended December 31, 2021, with income of HK $747 million, down 12.1% from the same period last year; loss attributable to the company's owners was HK $401 million, down 83.5% from the same period last year; and basic loss per share was HK4.5 cents per share.

During the year, due to the continuing impact of COVID-19 's outbreak and the tight operating cash flow caused by the long-term challenging operating environment, the Group continued to suspend operation of most of its production facilities. The suspension of operations and the consumption of most of the inventory in the previous year led to a decline in sales. As a result, the group's consolidated income for the year decreased by 12.1%.